WHO recommendation on advance misoprostol distribution to

WHO recommendation on advance misoprostol distribution to misoprostol Misoprostol is a prostaglandin E1 analogue used to reduce the risk of NSAID-induced gastric ulcers and to terminate pregnancies misoprostol misoprostol on its own, and mifepristone in combination with misoprostol These medications, when used correctly, successfully terminate 80-95% of

misoprostol OBJECTIVE : To compare the efficacy and safety of a 200-microgram misoprostol vaginal insert with a 10-mg dinoprostone vaginal insert for reducing the time

misoprostol Recommendation: · Mifepristone 200mg orally followed 1-2 days later by misoprostol 800mcg buccally, sublingually or vaginally · After 9 weeks gestation, Do not take misoprostol to prevent ulcers if you are pregnant or plan to become pregnant Misoprostol may cause miscarriages,